| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1158505T |
| P356 | DOI | 10.1371/JOURNAL.PONE.0158505 |
| P932 | PMC publication ID | 4938603 |
| P698 | PubMed publication ID | 27391605 |
| P50 | author | David J Venzon | Q56925544 |
| Michael A Thomas | Q110416123 | ||
| Marjorie Robert-Guroff | Q30651738 | ||
| Iskra Tuero | Q30651764 | ||
| P2093 | author name string | Tinashe Nyanhete | |
| P2860 | cites work | E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus | Q37110666 |
| The adenoviral E1B 55-kilodalton protein controls expression of immune response genes but not p53-dependent transcription | Q37145192 | ||
| Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge | Q37297052 | ||
| Effect of NKG2D ligand expression on host immune responses | Q37764003 | ||
| Hepatitis C virus-specific cellular and humoral immune responses following immunization with a multi-epitope fusion protein | Q39466259 | ||
| Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex | Q39593524 | ||
| Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. | Q43112464 | ||
| Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization | Q44592013 | ||
| China approves world's first oncolytic virus therapy for cancer treatment | Q45419325 | ||
| Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development | Q56993265 | ||
| Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses | Q64377680 | ||
| Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin | Q28731982 | ||
| Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication | Q33649728 | ||
| Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. | Q33786386 | ||
| Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting | Q34007261 | ||
| Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection | Q34562704 | ||
| From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development | Q34577135 | ||
| CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD | Q34707286 | ||
| Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors | Q35021632 | ||
| HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques | Q35032794 | ||
| Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. | Q35061529 | ||
| A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe | Q35785031 | ||
| IgG2a restriction of murine antibodies elicited by viral infections | Q36352342 | ||
| Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection | Q36404019 | ||
| Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study | Q36621905 | ||
| Packaging capacity and stability of human adenovirus type 5 vectors. | Q36653293 | ||
| E1A and E1B proteins inhibit inflammation induced by adenovirus | Q36854089 | ||
| Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport | Q36894173 | ||
| Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting | Q36954239 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | e0158505 | |
| P577 | publication date | 2016-07-08 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector | |
| P478 | volume | 11 |
| Q96640817 | Mucosal-associated invariant T (MAIT) cells provide B-cell help in vaccinated and subsequently SIV-infected Rhesus Macaques |
| Q40059020 | Novel viral vectors in infectious diseases |
| Q41699675 | Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer |
Search more.